Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

With PFA becoming physicians’ preferred ablation method for treating AFib, Abbott is pushing to catch up with rival systems ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

Though late to the party compared to other industry leaders, Abbott joins a pulsed field ablation market poised for ...

Boston Scientific continues to successfully expand its operations across various geographies outside the United States.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, ...

The combined FARAWAVE™ catheter and module mark the next generation of cardiac pulsed field atrial fibrillation ablation procedures ...

The stock rose during the quarter after the company reported better-than-expected organic growth and raised its earnings guidance, driven by continued strength in FARAPULSE, its atrial ...

The GalaFlex Lite scaffold. [Image courtesy of BD] BD (NYSE: BDX) + announced today that investigators treated the first patient in a study of its GalaFlex Lite scaffold system. The FDA ...